



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/11/28
(87) Date publication PCT/PCT Publication Date: 2018/06/07
(85) Entrée phase nationale/National Entry: 2019/05/28
(86) N° demande PCT/PCT Application No.: IB 2017/057436
(87) N° publication PCT/PCT Publication No.: 2018/100483
(30) Priorité/Priority: 2016/11/29 (GB1620119.6)

(51) Cl.Int./Int.Cl. *C07K 14/705* (2006.01),
C07K 16/22 (2006.01)
(71) Demandeur/Applicant:
PHARMAFOX THERAPEUTICS AG, CH
(72) Inventeurs/Inventors:
VRIJBLOED, JAN WILLEM, CH;
BOIDO, MARINA MARIA, IT;
BUTENKO, OLENA, CZ;
SCHELLINO, ROBERTA, IT
(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : COMPOSES D'AMELIORATION DES PERFORMANCES MUSCULAIRES
(54) Title: MUSCLE PERFORMANCE IMPROVEMENT COMPOUNDS




Figure 1

(57) **Abrégé/Abstract:**

A compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 June 2018 (07.06.2018)



(10) International Publication Number
WO 2018/100483 A1

- (51) International Patent Classification:
C07K 14/705 (2006.01) C07K 16/22 (2006.01)
- (21) International Application Number:
PCT/IB2017/057436
- (22) International Filing Date:
28 November 2017 (28.11.2017)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1620119.6 29 November 2016 (29.11.2016) GB
- (71) Applicant: PHARMAFOX THERAPEUTICS AG
[CH/CH]; Untere Fuchsrainstrasse 16, CH-4313 Möhlin
(CH).
- (72) Inventors: VRIJBLOED, Jan Willem; Untere Fuchsrainstrasse 16, CH-4313 Möhlin (CH). BIDO, Marina Maria; V. Fratelli Cervi 13, 10042 Nichelino (TO) (IT). BUTENKO, Olena; Humpolecka 1938/8, 14000 Prague (CZ). SCHELLINO, Roberta; Via Garesio 33/2, 10126 Torino (IT).
- (74) Agent: MCSTE, John Anthony; Teemac GmbH, Kantonsstrasse 7, CH-4416 Bubendorf (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: MUSCLE PERFORMANCE IMPROVEMENT COMPOUNDS




Figure 1

(57) Abstract: A compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems.

WO 2018/100483 A1

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

MUSCLE PERFORMANCE IMPROVEMENT COMPOUNDS

This disclosure relates to a method of treating pathological disorders or diseases affecting the function of muscles and to compounds for use in such treatments. The methods are particularly
5 suitable for treating, preventing, ameliorating or diagnosing pathological disorders.

Muscles are the contractile tissue responsible for all movement in living organisms. Any loss of muscle function is invariably harmful to a greater or lesser extent. Key elements of muscle function are strength, power and endurance. Muscle strength is the amount of force a muscle, or group of
10 muscles, can exert upon maximal contraction, generally against an external load. Muscle strength is expressed as the greatest measurable force that can be exerted by a muscle or muscle group to overcome resistance during a single, maximal effort. Muscle power is force developed quickly and combines strength and speed. It is the rate of performing work. Muscular endurance is the ability of a muscle or group of muscles to sustain in a prolonged fashion or repeatedly exert force against
15 resistance.

These performances can be evaluated by regular assessments of a subject in a testing regime, such as an exercise machine. Most important is the loss of muscle endurance. For example, improvement in a 6-minute walking test or "6MWT" (see, for example, Bautmans *et al* (BMC
20 Geriatr. 2004 Jul 23;4:6)) and Enright (Respir Care. 2003 Aug;48(8):783-5) is a prerequisite for approval by regulatory authorities such as the US Food and Drug Administration of a drug intended to treat pathological disorders affecting the functioning of the muscle.

There are many pathological disorders that can lead to the loss of muscle function. As used herein,
25 a "pathological disorder" includes, but is not limited to, neuromuscular diseases. Neuromuscular diseases is a very broad term that encompasses many diseases and ailments that impair the functioning of the muscles, either directly, being pathologies of the voluntary muscle, or indirectly, being pathologies of nerves or neuromuscular junctions.

30 One pathological disorder that can lead to loss of muscle function is muscle atrophy. There are many causes of muscle atrophy, including the result of treatment with a glucocorticoid such as cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone. The muscle atrophy can also be a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barre syndrome, peripheral neuropathy, or
35 exposure to environmental toxins or drugs).

In addition, the muscle atrophy can be a result of myopathy, such as myotonia; a congenital myopathy, including nemaline myopathy, multi/minicore myopathy and myotubular (centronuclear) myopathy; mitochondrial myopathy; familial periodic paralysis; inflammatory myopathy; metabolic

myopathy, such as caused by a glycogen or lipid storage disease; dermatomyositis; polymyositis; inclusion body myositis; myositis ossificans; rhabdomyolysis and myoglobinurias.

The myopathy may be caused by a muscular dystrophy syndrome, such as Duchenne, Becker,
 5 myotonic, fascioscapulohumeral, Emery-Dreifuss, oculopharyngeal, scapulohumeral, limb girdle, Fukuyama, a congenital muscular dystrophy, or hereditary distal myopathy. The musculoskeletal disease can also be osteoporosis, a bone fracture, short stature, or dwarfism.

Other pathological disorders that can lead to the loss of muscle function are adult motor neuron
 10 disease, infantile spinal muscular atrophy, amyotrophic lateral sclerosis, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conduction block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional insufficiency, cancer, AIDS, fasting, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, burn injury, chronic
 15 obstructive pulmonary disease, liver diseases (examples such as fibrosis, cirrhosis), sepsis, renal failure, congestive heart failure, ageing, space travel or time spent in a zero gravity environment.

Examples of age-related conditions that may be treated include, sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis,
 20 osteoarthritis, immunologic incompetence, high blood pressure, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, frailty, memory loss, wrinkles, impaired kidney function, and age-related hearing loss; metabolic disorders, including Type II Diabetes, Metabolic Syndrome, hyperglycemia, and obesity. Of course, patients may simultaneously suffer from one or more of these conditions,
 25 for example, sarcopenia and pulmonary emphysema, or sarcopenia and impaired kidney function.

Other conditions that are considered to be "pathological disorders" as recited herein include acute and/or chronic renal disease or failure, liver fibrosis or cirrhosis, cancer such as breast cancer, Parkinson's Disease; conditions associated with neuronal death, such as ALS, brain atrophy, or
 30 dementia and anemia. In addition, there are losses suffered as a consequence of age, trauma or inactivity.

Further conditions include cachexia, cachexia associated with a rheumatoid arthritis and cachexia associated with cancer.

35

To date, very few reliable or effective therapies have been developed to treat these disorders. Individual aspects of muscular problems have been addressed. For example, one potential avenue of treatment for loss of muscle mass is the inhibition of myostatin. Myostatin, sometimes referred to as GDF-8 (growth differentiation factor-8), is one of a family of dimeric growth and differentiation
 40 factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally

related signalling proteins. These proteins signal through a heterodimeric complex of receptor serine kinases which include at least two type I receptors, ActRIB (ALK4) and ActRIC (ALK7) and two type II receptors, ActRIIA (ACVR2A) and ActR2B (ACVR2B). These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signalling while type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding resulting in the phosphorylation of type I receptors by type II receptors.

10 The activin receptor II B (ActR2B) is a receptor for myostatin (GDF8) but numerous other members of the TGF-beta super family, such as Activin B, Activin AB, Inhibin A, Inhibin B, GDF3, GDF1 1 , Nodal, BMP2, BMP4, BMP7, BMP9, and BMP10 bind to and activate ActR2B as well (see, for example Tsuchida *et al* (Endocrine journal 2008 55(1), 11-21). Blocking the interactions of ActR2B with its ligands can lead to beneficial physiological effects. The interaction between myostatin and this receptor regulates the inhibition of skeletal muscle differentiation via the Smad-dependent pathway. (SMADs are intracellular proteins that transduce extracellular signals from transforming growth factor beta ligands, like myostatin to the nucleus where they activate downstream gene transcription). Thus, by inhibiting or preventing myostatin from binding to ActR2B, one can induce the formation of skeletal muscle.

20

Various groups have looked into this. Bogdanovich *et al* (Nature, 2002, 420:418-421) describes that anti-myostatin antibodies were able to block myostatin, resulting in an increase in muscle mass in a mouse model of Duchenne muscular dystrophy. Bradley *et al* (Cell Mol. Life. Sci. 2008, 65:2119-2124) have reviewed the different available approaches for modulating the myostatin/ActR2B interaction, including the aforementioned anti-myostatin antibodies, inhibiting the release of mature myostatin by administering the myostatin propeptide, administering follistatin to block the myostatin receptor, administering HDAC inhibitors to induce follistatin production, administering an altered myostatin peptide which prevents myostatin from binding the receptor and administering a soluble decoy receptor for myostatin.

30

Myostatin acts to inhibit muscle fibre growth and muscle stem cell growth. Studies have shown that animals either lacking myostatin or treated with substances that block the activity of myostatin have significantly larger muscle mass. Furthermore, individuals who have mutations in both copies of the myostatin gene have significantly increased muscle mass and in many cases are stronger than normal. In a particular case, described in N Engl J Med 2004; 350:2682-2688 (June 24, 2004), a baby born with unusually muscular development turned out to have a deficiency of myostatin, believed due to a defect in the gene responsible for its production.

40

A number of recent publications have sought to exploit this as a treatment, for example:

- Myostatin binding proteins such as ActR2B polypeptides (e.g. US7842663 and US8614292),
- follistatin (e.g. US6004937)
- anti-ActR2B antibodies (e.g. US 8,551,482)
- anti-myostatin antibodies (e.g., US7261893, US8063188, US8415159, US8551482 and
- 5 US8710212)
- anti-activin antibodies (e.g.US 20150037339 A1, WO 2009137075 A1)

Muscular hypertrophy and/or atrophy is not the whole story. Another factor is denervation. Muscle contraction is triggered by impulse from the nerves through release of electrical and

10 chemical messages. Nerves also provide the muscle fibers with a number of trophic factors, essential to the well-being and proper functioning of the muscle. The connection between nerves and muscle occurs via a highly complex synaptic structure called the neuromuscular junction (NMJ). Loss of NMJs results in the reduction of muscular function, independently of the anatomical and biochemical integrity of the muscle itself.

15

Some approaches have focussed on preventing loss of neuro-muscular junctions. For correct maintenance of NMJs, it has been shown by, for example, Wu *et al* (Development. 2010 Apr;137(7):1017-33. doi: 10.1242/dev.038711) and Tezuka et al (Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16556-61) that agrin is important for their formation and maintenance of a

20 neuromuscular junction.

It has nevertheless been found that even the combination of increased muscle mass and treatment seeking to retain NMJs does not prevent the loss of muscle performance (measured by the performance of suitably treated mice on a treadmill). In short, while there are a number of methods

25 for improving individual aspects of muscle problems, there currently exists nothing that can counteract the overall loss of muscle performance.

It has now been found that a particular group of linked proteins, polypeptides and monoclonal antibodies has given exceptional results in improving muscle performance. Therefore, there is

30 provided a compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities.

35 There is additionally provided a method of improving muscle performance, comprising the administration of an effective amount of a compound as hereinabove defined.

By "improving muscle performance" is meant that muscular endurance especially is improved. It is a surprising fact that, although the compounds hereinabove defined do not provide much more

40 muscle mass (myostatin) nor do they cluster acetyl choline receptors efficiently (at least 100-1000

times lower than a fully active agrin fragment), the overall muscular performance as measured by the endurance is remarkably improved. This can be demonstrated by the experimental methods hereinafter described.

- 5 With respect to amino acid sequences suitable for use in, and described in, this disclosure, the sequences should be at least 75% identical to those set forth hereinunder. More particularly, they may be 80%, 85%, 90% or 95% identical, most particularly 95% identical. In the case of inserts in the agrin (described in detail hereinunder), the inserts should be at least 95% identical. In a particular embodiment, all amino acid sequences are at least 95% identical.

10

The first component is the nLG3 domain from the C-terminus of agrin. Agrin is a large heparan proteoglycans with a molecular weight of 400-600 kDa. (Database accession number NP—940978). The protein core consists of about 2000 amino acids and its mass is about 225 kDa. It is a multidomain protein composed of 9 K (kunitz-type) domains, 2 LE (laminin-EGF-like) domains,
 15 one SEA (sperm protein, enterokinase and agrin) domain, 4 EG (epidermal growth factor-like) domains and 3 LG (laminin globular) domains. Agrin is a very important protein and agrin-deficient mice die at birth due to respiratory failure. This is caused by the fact that agrin is strictly required for the proper innervation of muscle fibers and that these mice are not able to build proper NMJs.

- 20 Agrin exists in several splice variants and can be expressed as a secreted protein, containing the N-terminal NtA (N-terminal agrin) domain, which is the most abundant form of agrin and the predominant form expressed in motor neurons. It is produced in the soma of the neurons, transported down the axon and released from the axon ending of the motor nerve into the synaptic cleft of the NMJ. Here it acts as an agonist of LRP4 and may also become a component of the
 25 basal lamina. In the CNS, most agrin is expressed as a type-II transmembrane protein by alternative splicing at the N-terminus lacking the N-terminal NtA domain (Bezakova and Ruegg, 2003).

- The serine/threonine (S/T) rich segments in agrin are responsible for a high degree of
 30 glycosylation, containing several glycosylation and glucosaminoglycan attachment sites giving rise to the big mass of the proteoglycan. The C-terminal, 75 kDa moiety of agrin starting with the first EG domain, is required for full activity in acetylcholine receptor (AChR) clustering activity on muscle cells, although the most C-terminal 20 kDa fragment is sufficient to induce AChR aggregation (Bezakova and Ruegg, 2003). Several binding sites for interaction partners of agrin,
 35 including α -dystroglycan, heparin, some integrins and LRP4, are mapped to the C-terminal region. The large heparansulfate side chains are binding sites for heparin binding proteins, e.g some growth factors.

- In the C-terminal part of human agrin, there are 2 alternative splice sites y and z At the y-site, there
 40 may be inserts of 0, 4, 17 or 21 (4+17) amino acids and at the z site there may be inserts of 0, 8,

11 or 19 (8+11) amino acids. The function of the four inserted amino acids in the y-site is to create a heparin binding site. Motor neurons express predominantly y4 agrin. The most important splice site of agrin in respect of NMJ maturation is the z-site, giving agrin the ability to be active as an acetylcholine-receptor clustering agent. It is well known that full-length agrin containing the

5 insertion of 8 amino acids at the z-site in presence of the 4-amino acid insert in splice site y (y4z8) generates an agrin variant with a half maximal AChR clustering activity of 35 pM in cultured myotube clustering assays. The insertion of 11 amino acids gives rise to a half-maximal AChR clustering activity while the 19 amino acid insertion results in a half-maximal AChR clustering activity of 110 pM. Agrin without an insertion at this site is not active in clustering acetylcholine-

10 receptors on the in-vitro cultured myotubes (Bezakova and Ruegg, 2003). Thus, the most active form of agrin in the clustering assay is the y4z8 variant, which is expressed by motor neurons.

A 40 kDa C-terminal fragment of agrin (y4z8) containing the LG2, EG4 and the LG3 domains was found to be active in AChR clustering with an EC50 of 130 pM in the AChR clustering activity while

15 shorter fragments have only lower activities. The C-terminal LG3 domain with the z8 insertion, the so-called LG3z8 domain, exhibits a half maximal AChR clustering activity of only 13 nM, which is a factor 100 fold lower than the 40 kDa fragment (Bezakova and Ruegg, 2003).

During the development and maturation of the NMJ, agrin is a key player of molecules involved in

20 the clustering of acetylcholine receptors. While NMJs are destabilized by the neurotransmitter acetyl choline, agrin, which is secreted by the motor neuron, stabilizes and increases the clusters of the AChR's via phosphorylation of MuSK, a membrane bound receptor tyrosine kinase. The interaction of agrin with MuSK is postulated to be mediated via LRP4, a low-density lipoprotein receptor (LDLR)-related protein. It was found that agrin (y4z8) has a 10-fold higher affinity to LRP4

25 than agrin (y4z0) giving rise to the differential AChR clustering activity of the different agrin splice variants observed in the *in vitro* cultured myotube assays. Upon agrin binding, LRP4 causes self-phosphorylation of MuSK, which then activates the signal cascade for the expression and clustering of acetylcholine receptors. It has been shown that a 44-kD fragment of agrin leads to the formation of clusters of acetyl choline receptors on the surface of muscle cells (see Hettwer *et al*

30 (PLOS ONE February 2014. Vol.9, Issue 2, e88739)), which is believed to be the initial step in the formation of a NMJ.

The term "LG3" as used in this disclosure means the mouse-derived 22 kDa C-terminal agrin fragment of SEQ ID NO: 1 (all sequences are appended to this disclosure and form part thereof).

35 The term "nLG3" as used in this disclosure means the LG3 fragment which further contains an insertion of 8, 11 or 19 amino acids at the z-site. The inserted sequences at the z-site are ELTNEIPA (z8, SEQ ID NO: 2), PETLDSRALFS (z11, SEQ ID NO: 3) or ELTNEIPAPETLDSRALFS (z19, SEQ ID NO: 4, a combination of SEQ ID NO: 2 and SEQ ID NO: 3). An example of nLG3 is SEQ ID NO: 5

The term “(h)LG3” as used in this disclosure means the human derived 22 kDa C-terminal agrin fragment of SEQ ID NO: 6. The term “(h)nLG3” as used in this disclosure means the (h)LG3 fragment which further contains an insertion of 8, 11 or 19 amino acids at the z-site. The inserted sequences at the z-site ELANEIPV (z8, SEQ ID NO: 7), PETLD SGALHS (z11, SEQ ID NO: 8) or
 5 ELANEIPVPETLD SGALHS (z19, SEQ ID NO: 9, a combination of SEQ ID NO: 7 and SEQ ID NO: 9). A particular example of (h)nLG3 is SEQ ID NO: 10

nLG3 may include additional amino acids at the N-terminus or C-terminus. Such additional amino acids at the N-terminus are e.g. present due to the method of preparation by recombinant synthesis
 10 and expression in suitable cells.

Proteins containing elongations at the N-terminus by one or more domains of agrin up to the natural N-terminus of agrin are also included, as well as glycosylated or in other ways post-translationally, enzymatically or chemically modified protein variants of human agrin.

15

The second component is selected from proteins or antagonistic antibodies that inhibit ActR2B-mediated signaling activity in the presence of myostatin. Examples of a second component as used herein refers to a protein or an antagonistic antibody such as actR2B (AcvRIIB, actRIIB), or acvRA (actR2, actRII), alk4, alk5. The term ActR refers to soluble extracellular part of the mouse ActR2B
 20 receptor as defined in SEQ ID NO: 11. This extracellular part is any part of the transmembrane protein that projects into the environment surrounding a cell. The term (h)ActR refers to extracellular part of the human ActR2B receptor as defined in SEQ ID NO: 12 (AAC64515.1, GI:3769443). Another example is follistatin as defined in SEQ ID NO: 25.

25 An example of a monoclonal antibody (mAb) that inhibits ActR2B-mediated signaling activity is ActRmAb (US8551482). Antibodies consist of a light chain (LC) and a heavy chain (HC). A typical example of the LC of ActRmAb (ActRmAb(LC)) is as defined in SEQ ID NO: 29. The HC of ActRmAb (ActRmAb(HC)) is as defined in SEQ ID NO: 28. The (h)nLG3 connected to ActRmAb(HC) (ActRmAb(HC)-(h)nLG3) is defined in SEQ ID NO: 30 Another example of an
 30 antibody is MyomAb (US8063188). This antibody is directed against myostatin and prevents binding of myostatin to the (h)ActR receptor. A typical example of the LC of MyomAb (MyomAb(LC)) is as defined in SEQ ID NO: 32. The HC of MyomAb (MyomAb(HC)) is as defined in SEQ ID NO: 31. The (h)nLG3 connected to MyomAb(HC) (MyomAb(HC)-(h)nLG3) is defined in SEQ ID NO: 33.

35

This ActR2B-mediated signal-inhibiting activity of mAbs may be readily ascertained by means of an assay. Such an assay can include, for example, a Smad-dependent reporter gene assay, inhibition of myostatin-induced Smad phosphorylation (P-Smad ELISA) and inhibition of myostatin-induced inhibition of skeletal muscle cell differentiation (for instance by a creatine kinase assay).

40

In some embodiments, the second component inhibits myostatin-induced signaling as measured in a Smad-dependent reporter gene assay at an IC₅₀ of 10 nM or less, 1 nM or less, or 100 pM or less.

- 5 In some instances, it is possible for a compound according to this disclosure to comprise an additional component, meaning that there will be three components, joined by two linking entities. The third component acts as a stabiliser component, that is, it increases *in vivo* serum half-life. This may be as a result of decreased destruction, decreased clearance by the kidney, or other pharmacokinetic effect. "*In vivo* serum half-life" refers to the half-life of a protein circulating in the
- 10 blood of an organism. Fusions with the Fc region of an immunoglobulin (IgG molecule) are known to confer desirable pharmacokinetic properties and increase serum half-life on a wide range of proteins. The term "Fc region of an IgG molecule" refers to the Fc domain of an immunoglobulin of the isotype IgG, as is well known to those skilled in the art. The Fc region of an IgG molecule is that portion of IgG molecule (IgG1, IgG2, IgG3, and IgG4) that is responsible for increasing the *in vivo*
- 15 serum half-life of the IgG molecule.

The third component may also be selected so as to confer a desired property. For example, some domains are particularly useful for isolation of the resulting proteins by affinity chromatography. For the purpose of affinity purification, relevant matrices for affinity chromatography, such as

20 glutathione-, amylase-, and nickel- or cobalt-conjugated resins are used. Many of such matrices are available in "kit" form, such as the Pharmacia GST purification system and the QIAexpress.TM. system (Qiagen) useful with (HIS.sub.6) fusion partners. As another example, the third domain may be selected so as to facilitate detection of the ActR2B polypeptides. Examples of such detection domains include the various fluorescent proteins (e.g., GFP) as well as "epitope tags," which are

25 usually short peptide sequences for which a specific antibody is available. Well known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus haemagglutinin (HA), and c-myc tags. In some cases, the third domain might have a protease cleavage site, such as for Factor Xa or Thrombin, which allows the relevant protease to partially digest the fusion proteins and thereby liberate the recombinant proteins therefrom. The liberated

30 proteins can then be isolated from the third domain by subsequent chromatographic separation. In certain preferred embodiments, the ActR domain and the (h)nLG3 domain are linked to a domain that stabilizes the resulting polypeptide *in vivo*.

A typical example of a third component is an "Fc" domain SEQ ID NO: 14.

35

Likewise, fusions to human serum albumin can confer desirable properties. Other types of fusion domains that may be selected include multimerizing (e.g., dimerizing, tetramerizing) domains and functional domains (that confer an additional biological function, such as further stimulation of muscle growth).

A linking entity is a short stretch of amino acids, linking two protein components. This unstructured linker may correspond to the roughly 15 amino acid unstructured region at the C-terminal end of the extracellular domain of ActR2B (the "tail"), or it may be an artificial sequence of between 5 and 15, 20, 30, 50 or more amino acids that are relatively free of secondary structure. A linker may be
 5 rich in glycine and proline residues and may, for example, contain repeating sequences of threonine/serine and glycines. Often multiple repeats of the sequence gggs are used (Glycin-Glycin-Glycin-Serin). Glycin gives flexibility and Serin is polar. A linking may be rich in glycine and proline residues and may, for example, contain repeating sequences of threonine/serine and glycines (e.g., TG.sub.4 or SG.sub.4 repeats). A typical linker sequence "L" is as defined in SEQ ID
 10 NO: 13. A fusion protein may include a purification subsequence, such as an epitope tag, a FLAG tag, a polyhistidine sequence, and a GST fusion.

Examples of ActR domain containing protein linked to a Fc domain are ActR-Fc (SEQ ID NO: 19), Fc-ActR (SEQ ID NO: 20) and (h)ActR-Fc (SEQ ID NO: 21). (Cadena et al. J Appl Physiol 109:
 15 635–642, 2010). Example of a follistatin linked to an Fc domain is defined in SEQ ID NO: 26.

Examples of nLG3 domain-containing protein linked to a Fc domain are nLG3-Fc (SEQ ID NO: 16), Fc-nLG3 (SEQ ID NO: 15) and Fc-(h)nLG3 (SEQ ID NO: 17). An example of a LG3 domain without
 insert Fc-(h)LG3 (SEQ ID NO: 18) was also constructed

20

Particular embodiments include the following components

- A-L-B
- B-L-A
- A-L-C-L-B
- 25 B-L-C-L-A
- C-L-B-L-A
- C-L-A-L-B
- B-L-A-L-C
- A-L-B-L-C
- 30 A-L-D
- D-L-A
- A-L-E
- E-L-A

in which

- 35 A represents an agrin nLG3 domain-containing protein,
- B represents an extracellular domain of the ActRIB, ActRIC, ActRIIA, ActR2B receptor protein and follistatin
- C represents a "stabiliser" domain,
- D represents ActR2B-mediated signal-inhibiting mAb against the ActRIB, ActRIC, ActRIIA, and
- 40 ActR2B receptor protein,

E represents ActR2B-mediated signal-inhibiting mAb against a member of the TGF-beta super family

L represents a linking entity.

5 particular combinations being B-L-C-L-A, D-L-A and E-L-A

Examples of these particular combinations are ActR-Fc-nLG3 as defined in SEQ ID NO: 22, (h)ActR-Fc-(h)nLG3 as defined in SEQ ID NO: 23. Fol-Fc-nLG3 as defined in SEQ ID NO: 27. The ActRmAb(HC) linked to (h)nLG3 (ActRmAb(HC)-(h)nLG3) as defined in SEQ ID NO: 30. The
10 MyomAb(HC linked to (h)nLG3) (MyomAb(HC)-(h)nLG3) as defined in SEQ ID NO: 33. The corresponding light chains of the antibodies need to be co-expressed with the heavy chains to create a fully functional antibody.

The heavy and light chains of the antibodies according to this disclosure may be expressed as
15 contiguous single-chain proteins, with the first and second components joined by the linking entity (see e.g. Bird et al., 1988 Science 242:423-426; Huston et al., 1988 Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al., 1990 Nature 348:552-554). The contiguous single chain protein can be linked to (h)nLG3.

20 The compounds of this disclosure may be made by known methods. For example, the DNA coding for the compound is expressed in suitable expression systems and the resulting protein is subsequently purified. Several prokaryotic and eukaryotic expression systems are suitable for the production and secretion of the compounds of the disclosure. Prokaryotic expression systems include, but are not limited to, expression in E. coli. Eukaryotic expression systems include
25 expression in mouse myeloma cells, baculovirus-mediated expression in insect cells, as well as expression in human embryonic kidney (HEK) cells, transient expression in Chinese hamster ovary (CHO) cells and stable expression in Pichia pastoris. These systems have the advantage that they can easily be adapted to serum-free conditions to reduce the amount of contaminating proteins in the supernatant and can be adapted for large scale production. In addition, a variety of cell lines
30 may be used, including HEK293T and HEK293-cells, COS cells, CHO cells, HeLa cells, H9 cells, Jurkat cells, NIH3T3 cells, C127 cells, CV1 cells, CAP cells or SF cells.

The sequence of a component may be adjusted, as appropriate, depending on the type of
35 expression system used, as mammalian, yeast, insect and plant cells may all introduce differing glycosylation patterns that can be affected by the amino acid sequence of the peptide. In general, proteins for use in humans will be expressed in a mammalian cell line that provides proper glycosylation, such as HEK293 or CHO cell lines, although other mammalian expression cell lines are also expected to be useful.

The compounds of the disclosure may be purified by standard protein purification technologies. Immunoglobulins G may be purified using protein A or G. His-tagged protein can be purified using IMAC, but ion exchange chromatography or affinity purification using a heparin column can be used as well. Purification via an antibody raised against the C-terminal part of agrin can also be
 5 used. The eluted protein can then further be purified using a hydroxyapatite column or by gel filtration.

The compounds of this disclosure are useful in pharmaceutical compositions. The disclosure therefore provides a pharmaceutical composition comprising at least one compound as
 10 hereinabove described, formulated together with a pharmaceutically-acceptable carrier.

The pharmaceutical compositions of this disclosure are particularly useful for the treatment of pathological conditions leading to the loss of muscle function. Non-limiting examples of such conditions include:

15

- muscle atrophy as a result of treatment with a glucocorticoid such as cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone;
- muscle atrophy as a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barre syndrome, peripheral neuropathy,
 20 or exposure to environmental toxins or drugs);
- muscle atrophy as a result of myopathy, such as myotonia; a congenital myopathy, including nemaline myopathy, multi/minicore myopathy and myotubular (centronuclear) myopathy; mitochondrial myopathy; familial periodic paralysis; inflammatory myopathy; metabolic myopathy, such as caused by a glycogen or lipid storage disease; dermatomyositis;
 25 polymyositis; inclusion body myositis; myositis ossificans; rhabdomyolysis and myoglobinurias;
- myopathy caused by a muscular dystrophy syndrome, such as Duchenne, Becker, myotonic, fascioscapulohumeral, Emery-Dreifuss, oculopharyngeal, scapulohumeral, limb girdle, Fukuyama, a congenital muscular dystrophy, or hereditary distal myopathy
- musculoskeletal diseases such as osteoporosis, bone fracture, short stature, or dwarfism;
 30
- adult motor neuron disease, infantile spinal muscular atrophy, amyotrophic lateral sclerosis, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conductor block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional
 35 insufficiency, cancer, AIDS, fasting, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, burn injury, chronic obstructive pulmonary disease, liver diseases (examples such as fibrosis, cirrhosis), sepsis, renal failure, congestive heart failure, ageing, space travel or time spent in a zero gravity environment.

- age-related conditions such as sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, immunologic incompetence, high blood pressure, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, frailty, memory loss, wrinkles, impaired kidney function, and age-related hearing loss; metabolic disorders, including Type II Diabetes, Metabolic Syndrome, hyperglycemia, and obesity. Of course, patients may simultaneously suffer from one or more of these conditions, for example, sarcopenia and pulmonary emphysema, or sarcopenia and impaired kidney function.
- pathological disorders such as acute and/or chronic renal disease or failure, liver fibrosis or cirrhosis, cancer such as breast cancer, Parkinson's Disease; conditions associated with neuronal death, such as ALS, brain atrophy, or dementia and anemia. In addition, there are losses suffered as a consequence of age, trauma or inactivity.
- further conditions such as cachexia, cachexia associated with a rheumatoid arthritis and cachexia associated with cancer.

The pharmaceutical compounds of the disclosure can also be administered in combination therapy, i.e. combined with other agents. For example, the combination therapy can include an anti-ActR2B antibody of the present disclosure combined with at least one other muscle mass/strength increasing agent, for example, IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActR2B but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. The pharmaceutical compounds of the disclosure also can be administered in combination therapy with Nusinersen or similar compounds. Nusinersen, an antisense oligonucleotide that modulates alternate splicing of the SMN2 gene, functionally converting it into SMN1 gene, is an investigational drug for spinal muscular atrophy.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier should be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g. by injection or infusion). Depending on the route of administration, the compound of this disclosure may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

The compounds of the disclosure may be in the form of pharmaceutically-acceptable salts. A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g. Berge, S. M., et

al., 1977 J. Pharm. Sci. 66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and di-carboxylic acids, phenyl-substituted
5 alkanolic acids, hydroxy alkanolic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chlorprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

10

A pharmaceutical composition of the disclosure also may include a pharmaceutically acceptable anti-oxidant. Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated
15 hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Examples of suitable aqueous and nonaqueous carriers that may be employed in the
20 pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

25

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of presence of microorganisms may be ensured both by sterilization procedures, supra, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to
30 include isotonic agents, such as sugars, sodium chloride, and the like into the compounds. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as, aluminum monostearate and gelatin.

Pharmaceutically-acceptable carriers include sterile aqueous solutions or dispersions and sterile
35 powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compounds of the disclosure is contemplated. Supplementary active compounds can also be incorporated into the compounds.

40

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compound can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, 5 and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, one can include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the compound. Prolonged absorption of the injectable compounds can be brought about 10 by including in the compound an agent that delays absorption for example, monostearate salts and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of agents enumerated above, as 15 required, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other agents from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active agent plus any additional desired 20 agent from a previously sterile-filtered solution thereof.

The amount of compound which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration. The amount of active agent which can be combined with a carrier material to 25 produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01 percent to about ninety-nine percent of active agent, from about 0.1 percent to about 70 percent, or from about 1 percent to about 30 percent of active agent in combination with a pharmaceutically acceptable carrier.

30

Dosage regimens are adjusted to provide the optimum desired response (e.g. a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral 35 compounds in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on 40 the unique characteristics of the active compound and the particular therapeutic effect to be

achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

For administration of the compound, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the ranges of 1-10 mg/kg or 3-7 mg/kg. An example treatment regime entails administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every three to 6 months. Alternatively, the compound may be administered about once a year or once only. Such administration may be carried out intravenously or subcutaneously. Dosage regimens for a compound of the disclosure include 1 mg/kg body weight or 3 mg/kg body weight by intravenous administration, with the antibody being given using one of the following dosing schedules: every four weeks for six dosages, then every three months; every three weeks; 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks.

The dosage should be one that causes an enhancement of muscle performance. In various embodiments the effect is on skeletal muscle. In various embodiments, the dosage causes muscle hypertrophy with no more than a proportional increase in the size of internal organs (e.g. heart, lungs, liver, kidneys). Such a proportional increase may be compared by measuring either mass or volume.

In some methods, two or more compounds according to this disclosure with different binding specificities may be administered simultaneously, in which case the dosage of each compound administered falls within the ranges indicated. Compound is usually administered on multiple occasions. Intervals between single dosages can be, for example, weekly, monthly, every three months, every six months or yearly. Intervals can also be irregular as indicated by measuring blood levels of compound to the target antigen in the patient. In some methods, dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 $\mu\text{g/ml}$ and in some methods about 25-300 $\mu\text{g/ml}$.

Alternatively, a compound can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the compound in the patient. In general, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated or until the patient shows partial or

complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

- Actual dosage levels of the compounds in the pharmaceutical compositions of the present disclosure may be varied so as to obtain an amount of the compound which is effective to achieve the desired therapeutic response for a particular patient, compound, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compounds of the present disclosure employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compounds employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- A "therapeutically effective dosage" of a compound of the disclosure can result in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction i.e. an increase in muscle mass and/or strength.
- A compound of the present disclosure can be administered by one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. Routes of administration for antibodies of the disclosure include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. In one embodiment the antibody is administered intravenously. In another embodiment the antibody is administered subcutaneously.

Alternatively, a compound of the present disclosure can be administered by a nonparenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic

acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g. Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

5 The compounds can be administered with medical devices known in the art. For example, in one embodiment, a compound of the disclosure can be administered with a needleless hypodermic injection device, such as the devices shown in U.S. Pat. Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556. Examples of well-known implants and modules useful in the present disclosure include: U.S. Pat. No. 4,487,603, which shows an implantable
10 micro-infusion pump for dispensing medication at a controlled rate; U.S. Pat. No. 4,486,194, which shows a therapeutic device for administering medicants through the skin; U.S. Pat. No. 4,447,233, which shows a medication infusion pump for delivering medication at a precise infusion rate; U.S. Pat. No. 4,447,224, which shows a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Pat. No. 4,439,196, which shows an osmotic drug delivery system having multi-
15 chamber compartments; and U.S. Pat. No. 4,475,196, which shows an osmotic drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art and include those made by MicroCHIPS.TM. (Bedford, Mass.).

In certain embodiments, the compounds of the disclosure can be formulated to ensure proper
20 distribution *in vivo*. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the compounds of the disclosure cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g. U.S. Pat. Nos. 4,522,811; 5,374,548; and 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug
25 delivery (see, e.g. V. V. Ranade, 1989 J. Clin Pharmacol. 29:685). Example targeting moieties include folate or biotin (see, e.g. U.S. Pat. No. 5,416,016); mannosides (Umezawa et al., 1988 Biochem. Biophys. Res. Commun 153:1038); antibodies (P. G. Bloeman et al., 1995 FEBS Lett. 357:140; M. Owais et al., 1995 Antimicrob. Agents Chemother. 39:180); surfactant protein A receptor (Briscoe et al., 1995 Am. J. Physiol. 1233:134); p120 (Schreier et al., 1994 J. Biol. Chem.
30 269:9090); see also K. Keinanen; M. L. Laukkanen, 1994 FEBS Lett. 346:123; J. J. Killian; I. J. Fidler, 1994 Immunomethods 4:273.

A further surprising and beneficial effect of the compounds of this disclosure is that they are much more specific myostatin inhibitors than those known to the art.

35

It is well known that myostatin blocking agents have multiple effects, not only on muscle fibers but also on satellite cells. Satellite cells are a heterogeneous population of stem and progenitor cells that are required for the growth, maintenance and regeneration of skeletal muscle. Myostatin

blocking agents switch on growth and differentiation of these muscle stem cells (McCroskery et al. (2003) J. Cell Biol. 162, 1135–1147).

Myostatin blocking agents have a different effect on muscle fibers; they switch off protein
 5 degradation of muscle filaments (responsible for muscle contraction) and turn on protein synthesis of muscle filaments (Curr Opin Support Palliat Care. 2011 Dec; 5(4): 334–341). Myosin is the name for a family of muscle protein filaments known for their role in muscle contraction – they comprise a family of ATP-dependent motor proteins and are known for their role in muscle contraction. During muscle contraction, muscle filaments, like myosin, can be damaged and need to be degraded and
 10 replaced by new filaments. It is known that a human mutation in muscle protein degradation leads to proximal muscle weakness and hypertrophic cardiomyopathy. In a paper by Olivé *et al* (Human Molecular Genetics, 2015, 1–13) it was demonstrated that the muscle fibers of a patient contained inclusions formed by myosin and myosin-associated proteins.

15 Myostatin blocking agents also block protein degradation of muscle filaments and it is therefore feasible that prolonged exposure to a myostatin inhibitor leads to an accumulation of damaged muscle filaments. This could be an unwanted side effect of myostatin blocking agents such as ActR-Fc, ActRmAb and MyomAb. This may explain the relatively low activity of these proteins in performance assays such as the treadmill.

20

The coupling of nLG3 to ActR-Fc, ActRmAb and MyomAb described in this disclosure has resulted in novel compounds that are more specific in their mode of action. Proteins such as ActR-Fc-nLG3, ActRmAb-nLG3 and MyomAb-nLG3 activate only satellite cells and do not have a direct effect on muscle fibers. Presently, it is unclear how such proteins reach this new level of specificity in their
 25 mode of action. One explanation, without limiting the scope of this disclosure in any way, could be that Act RIIB receptors use also LRP-proteins as co-receptor. It is very well known that nLG3 binds to LRP4. Binding to LRP4 is very important. The protein ActR-Fc-LG3, (note the difference between LG3 and nLG3) used as a control, leads to similar weight and muscle increase as ActR-Fc does, so the addition of a LG3 domain is not sufficient for this new activity (see figure 12). It is
 30 essential that the LG3 domain has an appropriate insert which makes it capable of binding to LRP4. This result also shows that a bulky residue at the C-terminus of ActR-Fc is not likely to be the reason for the novel effects of ActR-Fc-nLG3.

This disclosure therefore also provides a method of specifically activating muscle satellite cells of
 35 skeletal muscle in the absence of direct effect on muscle fibers, comprising the treatment of the muscle with a compound as hereinabove described.

The disclosure is further described with reference to the following examples and associated Figures, which depict particular embodiments and which are not in any way limiting.

A more detailed exposition of the Figures 1-11 is provided below, but the basic details are as follows:

Figure 1 shows the formation of acetyl Choline receptor clusters (dots).

5 **Figure 2** shows the coomassie-stained SDS-PAGE gel of a number of compositions

Figure 3 shows the relative body weight increase over time.

Figure 4 shows the relative muscle weights for mice treated with vehicle and a number of compounds.

Figure 5 shows the rotarod performance of treated mice.

10 **Figure 6** shows relative body weight increase over time.

Figure 7 shows relative muscle wet weights.

Figure 8 shows the treadmill performance of the aged mice.

Figure 9 shows the number of motivational electrical pulses per minute during the treadmill runs.

Figure 10 shows the mean grip strength (GS) performance of the mice during week three of
15 vehicle dosing (GS before treatment).

Figure 11 Summary of muscle pathology.

Figure 12 shows the relative body weight increase over time.

Synthesis of proteins

20 cDNAs were obtained commercially. The cDNAs were cloned via restriction enzymes NotI and HindIII into the mammalian gene expression vector pEvi3 (evitria AG, Switzerland). Plasmid DNA was prepared under low-endotoxin conditions using commercially-available DNA purification kits (Macherey Nagel, Germany). The protein Fc-nLG3 was obtained using SEQ ID NO: 34. The protein nLG3-Fc was constructed using SEQ ID NO: 35. Fc-(h)nLG3 was constructed using SEQ
25 ID NO: 36. Fc-(h)LG3 was constructed using SEQ ID NO: 37. Fc-ActR was constructed using SEQ ID NO: 38, ActR-Fc was constructed using SEQ ID NO: 39. (h)ActR-Fc was constructed using SEQ ID NO: 40. ActR-Fc-nLG3 was constructed using SEQ ID NO: 41.

(h)ActR-Fc-(h)nLG3 was constructed using SEQ ID NO: 42, (h)ActR-Fc-(h)LG3 was constructed
30 using SEQ ID NO: 43, ActRmAb(LC) was constructed using SEQ ID NO: 44 and ActRmAb(HC) was constructed using SEQ ID NO: 45. ActRmAb(HC)-(h)nLG3 was constructed using SEQ ID NO: 46. MyomAb(LC) was constructed using SEQ ID NO: 47, and MyomAb(HC) was constructed using SEQ ID NO: 48. MyomAb(HC)-(h)nLG3 was constructed using SEQ ID NO: 49. Fol-Fc and Fol-Fc-nLG3 were constructed using SEQ ID NO: 50 and SEQ ID NO: 51 respectively.

35

Production and Purification of the proteins

All proteins were produced by in CHO K1 cells. The seed was grown in eviGrow™ medium (evitria AG, Switzerland), a chemically defined, animal-component free, serum-free medium. Transfection and production were carried out in eviMake™ (evitria AG, Switzerland), an animal-component free,
40 serum-free medium, at 37°C and 5% CO₂. ActRmAb and MyomAb are generated by simultaneous

transfection with IgG heavy and light chain expression vector DNA. The resulting antibody are named ActmAb and MyomAb, respectively. ActRmAb-(h)nLG3 was made by simultaneous transfection of vector DNA generated with ActRmAb(HC)-(h)nLG3 and ActRmAb(LC). The resulting antibody is named ActmAb-(h)nLG3. MyomAb-(h)nLG3 was made by simultaneous transfection of
 5 vector DNA generated with MyomAb(HC)-(h)nLG3 and MyomAb(LC). The resulting antibody is named MyomAb-(h)nLG3.

Supernatants were harvested by centrifugation and sterile filtered (0.2 µm) at day 8 after transfection. The target proteins were subsequently purified via Protein A affinity chromatography
 10 on a Bio-Rad BioLogic DuoFlow FPLC system with PBS as wash buffer, 0.1 mol/l glycine pH 3.0 as elution buffer and 1 mol/l TRIS pH 10 as neutralization buffer.

Identification of proteins by SDS-PAGE Gel Electrophoresis

Each compound was eluted in 4X LDS Sample Buffer (Invitrogen) and 10X reducing agent
 15 (Invitrogen) to reach the concentration of 1µg. Samples were heated at 70°C for 10 minutes, and subsequently run on 4–12% Bis-Tris Plus gel (Invitrogen). Gels were run at 200V voltage for 35 minutes. Target protein fractions were identified by Coomassie staining of gel. Gels were left in Coomassie staining solution (0.26% Coomassie Blue, 10% Acetic Acid, 25% Methanol) for 4 hours. After removing Coomassie solutions, gels were then incubated in the destaining solution (10%
 20 Acetic Acid, 25% Methanol) overnight, in order to eliminate the excess dye. Gels were scanned and images were taken, using a densitometer (BioRad).

Acetyl Choline Receptor Clustering on C2C12 mouse cells.

C2C12 mouse muscle cells were cultured skeletal myoblasts from ATCC (ATCC-LGC Standards
 25 S.r.l., Italy) which were cultured in Dulbecco's Modified Eagle's Medium (DMEM) high glucose (Sigma, Italy) with 10% FBS (Sigma), containing 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all purchased from Invitrogen-Gibco). They were cultured for 2-3 days on 8 well chamber slides in the previous medium, then replaced with DMEM and 3% FBS, to obtain myotubes . Myotubes were incubated with agrin constructs at 10 µM (microM) for 24h and fixed
 30 with 2% paraformaldehyde for 20 min at RT. The samples were stained for the AChR by incubating the cells with Alexafluor 555-conjugated α-Bungarotoxin (1:500; Invitrogen, Italy) at RT for 1 h. The cells were then rinsed and coverslips were mounted with a drop of PB 0.1M. The levels of AChR clustering were compared by determining the average AChR cluster number in random fields, at a magnification of 40x with a fluorescent microscope.

35 Animal studies

Ethic Statement

All procedures involving the use of laboratory animals were performed in accordance with the Italian national (DL n. 116, G.U., Supp. 40, February 18, 1992; permit number 17/2010-B, June 30, 2010) and European Communities Council Directive 24 November 1986 (86/609/EEC).

Animals

Nine week-old animals

In one experiment nine-week-old male C57BL/6 mice (n=5 per group, Harlan, Italy) were
5 randomized with body weight and then treated subcutaneously with the proteins. The proteins used
are indicated in the figures. Phosphate Buffered Saline (PBS), pH 7.4 was used as vehicle control.
The dose was 10 mg/kg and is administrated three times per week, on day 1, 3, 5, 8, 10, 12 for a
two week treatment. The total dose for the mixture was 20 mg/kg, consisting of a 1:1 mix of ActR-
Fc and Fc-nLG3 so that each protein is given at 10 mg/kg. Body weights are determined three
10 times per week prior to dosing 25 days after start of administration, mice are euthanized with CO₂.
Gastrocnemius, quadriceps femoris and triceps brachii are collected and weighed.

22 month-old animals

In the aged mice experiment 24 male mice, strain C57/BL6 (purchase at Charles River, France) are
15 used. At the beginning of the experimental procedures, mice are 22 months old. Animals are
weighed, ear punched; mice are kept in regular cages, 5 per cage, under 12/12-h light/dark cycle,
with food and water available ad libitum. Injections were performed subcutaneously (10 mg/kg) 3
times per week during five consecutive weeks. For the 5 week treatment the compounds were
injected on day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33. Animals were split randomly
20 into three experimental groups: control group (PBS), which received injections of PBS, treated
groups AcrR-Fc-nLG3, and ActR-Fc.

Body Weight

Mice body weight was measured 5 times per week throughout the experiment.
25

Rotarod.

Rotarod measurements were done on a 7650 accelerating model of a Rotarod™ apparatus (Ugo
Basile, Italy)). The mouse is placed on the rod of a Rotarod. The rod slowly accelerates from 4 to
32 rpm. The time that a mouse stays on the rod is recorded and the test terminates when the
30 mouse is no longer able to remain on the rod. Maximum trial duration in the standard trial is 5
minutes. In the extended trial the maximum trial duration is 30 minutes. Rotarod performance of
different treatment groups is indicated. Standard deviations are indicated as error bars. (N = 5 for
each group). The standard trial was done on day 18 and day 21 of the treatment after two exercise
trials. The data is the average of four on two days. The extended trial is done on day 21 of the
35 treatment.

Treadmill Exercise

Mice were trained on a treadmill apparatus (Panlab, Harvard Apparatus) three times per week, in
the afternoon. The instrument has the capability of exercising up to five mice simultaneously in
40 individual lanes. Mice were trained on treadmill for 3 weeks before starting compound injections,

then for 3 weeks during compound/PBS dosing. Each mouse was tested using an accelerating treadmill protocol. Briefly, mice were properly acclimated to the treadmill prior to any experimentation. In the days before experimental runs, mice were placed on the treadmill in their respective lanes with shocking grids off and the belt moving and they were let to explore the instrument for minutes. During experimentation, mice were warmed up before running. For this, the belt was started at a low speed (16 cm/sec) and the shocking grids were gradually turned on to 0.2 mA. The duration of warm-up period was 2 minutes. After warm-up period, mice were tested for their running performances. The treadmill speed starts at 16 cm/sec and accelerated 1cm every minute. The acceleration continues until the mice reach exhaustion state. If a mouse received 10 or more shock per minute, this level is considered the exhaustion state and the experiment is stopped for that particular mouse. After exhaustion, shocking grid is deactivated and the mouse is returned to its cage. The running distance, the number of shocks taken in every minute, and the total number of shocks are evaluated for each mouse.

15 **Grip Strength test**

Forelimb grip strength was measured using a Grip Strength Meter (Ugo Basile, Varese, Italy). The control and treated mice were tested twice a week during the first six weeks of the experiments, and were tested 5 times per week in the last two weeks of experimentation. Mice were held by the tail and allowed to grasp a T-shaped bar with their forepaws. Once the mouse grasped the bar with both paws, the mouse was pulled away from the bar until the mouse released the bar. The digital meter displays the level of tension (in grams) exerted on the bar by the mouse. Each animal was given five consecutive tests, the lowest and the highest values were excluded by the analysis, and the average value was taken.

25 **Muscle isolation and storage**

Mice were sacrificed by cervical dislocation. After dislocation, the fresh skeletal muscles (triceps, quadriceps and gastrocnemius), were quickly dissected out from the skin and bones by forceps and scissors. The wet muscle weight was determined immediately after isolation. Then, muscles (3 for each mouse) were placed to the Peel-A-Way embedding molds (Sigma-Aldrich; E6032-1cs) containing Killik, embedding medium for criostate neutral (Bio-Optica, Milan; 05-9801), for cryosectioning. The minimal amount of Killik possible to cover the muscles was used, thus allowing rapid freezing to occur. Then the molds were immediately transferred in beaker filled with Isopentane (1-Methylbutane; Sigma-Aldrich; M32631) and dry ice (-80°C) for 20-40 seconds (longer contact times can result in the formation of cracks in the samples; insufficient time can result in freezing artifacts) and then were transferred the muscle sample to dry ice. For long-term storage samples were kept in freezer at -80°C.

The other three muscles for each mouse were quickly placed into a tube and covered with at least 1ml of RNAlater (Sigma-Aldrich), in order to stabilize and protect RNA with immediate RNase inactivation. Samples were kept at 4°C for 24 hours, then RNAlater were removed from tubes and samples were stored at -80°C until use.

Cryosectioning

Before cryosectioning, samples were placed into the cryostat for at least 20 minutes before further processing. The sample was mounted on the round metallic mount of the cryostat with Killik
 5 embedding medium. 20 μ m-thick cross sections were made and collected on warm (RT) gelatinated Superfrost slides (ThermoScientific Menzel Gläser (217655)). The sections were dried at RT for 1 hour and then stored at -20°C.

Morphometrical analysis of muscles

10 The cross-sections of mice muscles were stained with Hematoxylin Gill № 2 (Sigma-Aldrich (GHS232)) and Eosin Y 1% aqueous solution (H/E staining procedure see). Morphometrical analysis was performed on 3 cross-sections from each experimental group. The following parameters were evaluated: 1) area and perimeter of peripherally and centrally nucleated fibers, 2) the total number of nuclei referred to the number of fibers , 3) percentage of central nuclei referred
 15 to the total number.

Data analysis and statistics

Data are presented as means $\pm$ S.D. (standard deviation of the mean). Student's unpaired t-test
 20 was used to determine significant differences between the experimental groups. Values of *p < 0.05 were considered significant, **p < 0.01 very significant and *** p < 0.001 extremely significant.

The results obtained are explained with reference to the Figures.

Figure 1 shows the formation of acetylcholine receptor clusters (dots). 1A, Vehicle treated control;
 25 1B, Fc-nLG3; 1C, nLG3-Fc; 1D, ActR-Fc-nLG3. As expected at high concentration (10 μ M) of Fc-agrin (1B) and agrin-Fc (1C) AChR clusters were visible. However no clear clusters were visible using ActR-Fc-nLG3 (1D) and PBS (1A). Only incidental, probably spontaneous clusters, were visible. In addition, nLG3-Fc-ActR treated cells did also not show clusters on C2C12 treated cells. (results not shown). As expected AChR clusters appeared on nLG3-Fc and Fc-nLG3 treated
 30 C2C12 cells albeit only at high concentrations. No clusters were visible at 1 μ M. It is not clear why actR-Fc-nLG3 did not show AChR clusters. The "ActR" part of ActR-Fc-nLG3 might be inhibiting the formation of clusters. This might be caused by steric hindering making proper agrin binding impossible or the agrin and myostatin signaling pathways interfere.

35 **Figure 2** shows the coomassie stained SDS-PAGE gel of: Fc-nLG3 (Lane 1); nLG3-Fc (Lane 2); Fc-ActR (Lane 3); ActR-Fc (Lane 4); ActR-Fc-nLG3 (Lane 5); (h)ActR-Fc (Lane 6); Fc-(h)nLG3 (Lane 7); (h)ActR-Fc-(h)nLG3 (Lane 8); (h)ActR-Fc-(h)LG3 (Lane 9); ActRmAb (Lane10); ActRmAb-(h)nLG3 (Lane 11); MyomAb (Lane 12); MyomAb-(h)nLG3 (Lane 13). All observed protein bands are as expected. The protein bands of ActR and (h)ActR derivatives are fuzzy

because this protein is glycosylated and the degree of glycosylation generates multiple bands of the same protein.

Figure 3 shows the relative body weight increase over time. Nine weeks old mice were treated with vehicle, ActR-Fc, Fc-nLG3, ActR-Fc-nLG3 and a 1:1 mixture of ActR-Fc and Fc-nLG3 (Figure 2A); vehicle, (h)ActR-Fc, (h)Fc-(h)nLG3, and (h)ActR-Fc-(h)nLG3 (Figure 2B); vehicle, ActmAb and ActmAb-nLG3 (Figure 3C); vehicle, MyomAb and MyomAB-(h)nLG3 (Figure 2D). As expected ActR-Fc, ActR-Fc-nLG3, and the ActR-Fc + Fc-nLG3 mixture treated mice have significantly increased body weights compared to vehicle treated mice at day15. Surprisingly, ActR-Fc-nLG3 treated mice have a significantly lower body weight compared to ActR-Fc, ActR-Fc-nLG3, and the ActR-Fc + Fc-nLG3 mixture. Also (h)Fc-(h)nLG3, ActmAb-nLG3 MyomAb-(h)nLG3 have significantly lower body weight compared to their relative control compounds (h)ActR-Fc, ActmAb and MyomAb.

Figure 4 shows the relative muscle weights for mice treated with vehicle, ActR-Fc, Fc-nLG3, ActR-Fc-nLG3, a 1:1 mixture of ActR-Fc, Fc-nLG3, (h)ActR-Fc, Fc-(h)nLG3, (h)ActR-Fc-(h)nLG3, ActmAb, ActmAb-nLG3, MyomAb and MyomAB-(h)nLG3. The relative mean muscle weights for the Gastrocnemius, Quadriceps and Triceps was calculated compared to muscles of vehicle treated mice. The results of the relative muscle weights resemble the results of the total body weights. As expected all compounds except Fc-nLG3 have significantly increased relative muscle weights. Surprisingly, compounds carrying in addition nLG3, or the human version of nLG3 (h)nLG3, ActR-Fc-nLG3, (h)ActR-Fc-(h)nLG3 ActmAb-(h)nLG3 MyomAb-(h)nLG3 have significantly lower body weights compared to their control compounds.

Figure 5 shows the rotarod performance of the mice. The performance of ActR-Fc, Fc-nLG3, a 1:1 mixture of ActR-Fc and Fc-nLG3, ActmAb, MyomAb treated mice were not significantly increased. Surprisingly, the performance of the nLG3 resp (h)nLG3 containing compounds ActR-Fc-nLG3, ActmAb-nLG3 and MyomAB-(h)nLG3 were significantly increased compared to their control compounds ActR-Fc, ActmAb, MyomAb.

30

Figure 6 shows the relative body weight increase over time. The relative mean body weight for every week was calculated. All 22 old mice were treated with vehicle (PBS) during the first three weeks of the experiment. In the following five weeks the aged mice were treated with vehicle, ActR-Fc, and ActR-Fc-nLG3. After week 3 the ActR-Fc dosed animals reach highly significant levels of weight increased compared to vehicle. After week 3 ActR-Fc-nLG3 dosed animals have significantly increased body weight compared to vehicle but significantly lower than the body weights of ActR-Fc.

Figure 7 shows the relative muscle wet weights. The relative mean muscle weights for the Gastrocnemius, Quadriceps and Triceps was calculated compared to muscles of vehicle treated

40

mice. ActR-Fc dosed animals have highly significant levels of muscle weight increased compared to vehicle. ActR-Fc-nLG3 dosed animals are significantly increased in muscle weight compared to vehicle but significantly lower than the body weights of ActR-Fc.

5 **Figure 8** shows the treadmill performance of the aged mice. Figure 8A shows the treadmill performance during week three of vehicle dosing (before treatment). At this time point the performances of all groups are very similar. Figure 8B shows the mean treadmill performance during week 5 and 6 (after treatment). The performance of ActR-Fc and vehicle treated mice were lower after treatment than before treatment (not significant). It is likely that with increasing age the
10 treadmill performance of these mice is declining. Surprisingly, the performance of ActR-Fc-nLG3 treated mice was improved after treatment compared to before treatment ($p = X$). This shows that in spite of the mice being older, the treadmill performance improved. The performance of ActR-Fc-nLG3 in treated mice was significantly higher than vehicle and ActR-Fc treated mice. This shows that treatment with ActR-Fc-nLG3 improves the muscle endurance of the aged mice.

15

Figure 9 shows the mean number of motivational electrical pulses per minute during the treadmill runs at week 5 and 6. Mice require more electrical pulses when they get exhausted. ActR-Fc and vehicle treated mice needed more pulses than ActR-Fc-nLG3 treated mice. This was highly significant $p < 0.001$. Interestingly, in the first nine minutes all
20 three groups of mice required about the same number of pulses with no statistical differences. With increasing time on the treadmill, the performance of ActR-Fc-nLG3 treated mice was much better and the mice required fewer pulses than vehicle and ActR-Fc treated mice. This also clearly shows that mice treated with ActR-Fc-nLG3 have improved muscle endurance.

25

Figure 10 shows the mean grip strength (GS) performance of the mice during week three of vehicle dosing (GS before treatment). At this time point the performances of all groups are very similar. Figure 7B shows the mean grip strength (GS) performance during week 5 and 6 (GS after treatment). The performance of vehicle treated mice was lower after treatment than before
30 treatment (significant). The performance of ActR-Fc and ActR-Fc-nLG3 treated mice were higher after treatment than before treatment (significant). The GS performance of ActR-Fc-nLG3 and ActR-Fc treated mice were very similar after treatment and both are significantly increased compared to vehicle treated mice. So administration of the compound ActR-Fc-nLG3 has retained the increased muscle strength performance as ActR-Fc.

35 **Figure 11** Summary of muscle pathology. Cross sectional area (CSA), and number of nuclei per muscle fiber were determined for vehicle, ActR-Fc and ActR-Fc-nLG3 treated mice. From these results, the number of nuclei per CSA was calculated. In Figure 11 the relative values for CSA, and number of nuclei per nuclei per fiber and number of nuclei per CSA are depicted. ActR-Fc ($p < 0.001$) and ActR-Fc-nLG3 ($p < 0.05$) treated mice have

a statistically significantly increased CSA and number of nuclei per fiber compared to vehicle treated mice. In addition, compared to ActR-Fc-nLG3, ActR-Fc treated mice have a significantly increased CSA ($p<0.01$) and number of nuclei ($p<0.05$). However, compared to vehicle or ActR-Fc-nLG3, ActR-Fc treated mice have a significantly
 5 decreased number of nuclei per fiber area ($p<0.05$). Nuclei formation is promoted by the activity of the satellite cells. As satellite cells grow and differentiate they will fuse with an existing muscle fiber leading to more nuclei the muscle fiber.

Figure 12 shows the relative body weight increase over time. Nine weeks old mice were
 10 treated with vehicle, (h)ActR-Fc, (h)ActR-Fc-(h)nLG3, and (h)ActR-Fc-(h)LG3. At day 19 ActR-Fc, (h)ActR-Fc-(h)nLG3, and (h)ActR-Fc-(h)LG3 treated mice have significantly increased relative body weights ($p<0.001$, $p<0.05$, $p<0.001$ respectively) compared to vehicle treated mice. The relative body weights of (h)ActR-Fc-(h)LG3 and (h)ActR-Fc are not significantly different. Notably, (h)ActR-Fc-(h)LG3 treated mice have a significantly
 15 ($p>0.01$) higher body weight compared to (h)ActR-Fc-(h)nLG3. The two proteins differ only by an 8 amino acid sequence insert in (h)nLG3. This insert is responsible for binding to the LRP4 receptor, so (h)nLG3 binds to the LRP4 receptor whereas (h)LG3 does not bind. Mice treated with (h)ActR-Fc-(h)nLG3 show a similar growth curve as ActR-Fc-nLG3 (Figure 3).

20

From these results it seems likely that muscle growth of ActR-Fc-nLG3 is solely caused by growth of muscle stem cells, (i.e. satellite cells) which fuse with the muscle fiber leading to more nuclei. More nuclei will lead to higher protein synthesis in the muscle fiber leading to a modest increase in muscle and body weight increase in ActR-Fc-nLG3,
 25 (h)ActR-Fc-(h)nLG3, ActRmAb-nLG3 and MyomAb-nLG3 treated animals. Treatment with ActR-Fc also leads to more nuclei but the fiber growth is over proportional leading in fact to a lower nuclei density.

Claims:

1. A compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities.
2. A compound according to claim 1, selected from the group consisting of combinations of components, as follows:
 - A-L-B
 - B-L-A
 - A-L-C-L-B
 - B-L-C-L-A
 - C-L-B-L-A
 - C-L-A-L-B
 - B-L-A-L-C
 - A-L-B-L-C
 - A-L-D
 - D-L-A
 - A-L-E
 - E-L-A

in which

A represents an agrin nLG3 domain-containing protein,

B represents an extracellular domain of the ActRIB, ActRIC, ActRIIA, ActR2B receptor protein and follistatin

C represents a "stabilizer" domain,

D represents ActR2B-mediated signal-inhibiting mAb against the ActRIB, ActRIC, ActRIIA, and ActR2B receptor protein,

E represents ActR2B-mediated signal-inhibiting mAb against a member of the TGF-beta super family

L represents a linking entity.
3. A compound according to claim 2, in which the combinations is chosen from B-L-C-L-A, D-L-A and E-L-A.
4. A compound according to claim 2, in which A is selected from (h)nLG3 and proteins that are at least 75%, 80%, 85%, 90% and 95% identical thereto.

5. A compound according to claim 4, in which A is at least 75%, 80%, 85%, 90%, 95% and completely identical with SEQ ID NO:10.
6. A compound according to claim 2, in which B is selected from the extracellular domain from ActRIB, ActRIC, ActRIIA, ActR2B and follistatin, and proteins that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
7. A compound according to claim 6, in which B is selected from human ActR2B receptor as defined in SEQ ID NO: 12 (AAC64515.1, GI:3769443) and follistatin as defined in SEQ ID NO: 25.
8. A compound according to claim 2, in which C is an "Fc" domain selected from an IGG1, IGG2, IGG3 and IGG4 and "Fc" domains that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
9. A compound according to claim 2, in which C is an "Fc" domain as defined in SEQ ID NO: 14 and proteins that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
10. A compound according to claim 2, in which D is selected from signalling blocking mAbs against ActRIB, ActRIC, ActRIIA, ActR2B, or mAbs that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
11. A compound according to claim 6, in which D is a mAb as defined by ActRmAb(LC), (SEQ ID NO: 44) and ActRmAb(HC) (SEQ ID NO: 45) and mAbs that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
12. A compound according to claim 1, in which E is selected from signalling blocking mAbs against the TGF-beta super family, such as Activin B, Activin AB, Inhibin A, Inhibin B, GDF3, GDF1 1 , Nodal, BMP2, BMP4, BMP7, BMP9, and BMP10 and that are at least 75%, 80%, 85%, 90% and 95% identical thereto.
13. A compound according to claim 2, in which the linking entity is selected the roughly 15 amino acid unstructured region at the C-terminal end of the extracellular domain of ActR2B (the "tail"), and an artificial sequence of between 5 and 15, 20, 30, 50 or more amino acids that are relatively free of secondary structure.
14. A compound according to claim 6, in which E is a mAb as defined MyomAb(LC) SEQ ID NO: 32 and MyomAb(HC) SEQ ID NO: 31. and mAbs that are at least 75%, 80%, 85%, 90% and 95% identical thereto.

15. A compound according to claim 1, selected from the group consisting of ActR-Fc-nLG3 as defined in SEQ ID NO: 22, (h)ActR-Fc-(h)nLG3 as defined in SEQ ID NO: 23. Fol-Fc-nLG3 as defined in SEQ ID NO: 27, ActRmAb(HC) linked to (h)nLG3 (ActRmAb(HC)- (h)nLG3) as defined in SEQ ID NO: 30, MyomAb(HC linked to (h)nLG3) and (MyomAb(HC)-(h)nLG3) as defined in SEQ ID NO: 33.
16. A method of improving muscle performance, comprising the administration of an effective amount of a compound according to claim 1.
17. A pharmaceutical composition comprising at least one compound according to claim 1, formulated together with a pharmaceutically-acceptable carrier.
18. A method of treatment of a pathological condition leading to the loss of muscle function, comprising the administration of an effective amount of the compound according to claim 1, the pathological condition being one or more of:
- muscle atrophy as a result of treatment with a glucocorticoid such as cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone;
 - muscle atrophy as a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barre syndrome, peripheral neuropathy, or exposure to environmental toxins or drugs);
 - muscle atrophy as a result of myopathy, such as myotonia; a congenital myopathy, including nemaline myopathy, multi/minicore myopathy and myotubular (centronuclear) myopathy; mitochondrial myopathy; familial periodic paralysis; inflammatory myopathy; metabolic myopathy, such as caused by a glycogen or lipid storage disease; dermatomyositis; polymyositis; inclusion body myositis; myositis ossificans; rhabdomyolysis and myoglobinurias;
 - myopathy caused by a muscular dystrophy syndrome, such as Duchenne, Becker, myotonic, fascioscapulohumeral, Emery-Dreifuss, oculopharyngeal, scapulohumeral, limb girdle, Fukuyama, a congenital muscular dystrophy, or hereditary distal myopathy
 - musculoskeletal diseases such as osteoporosis, bone fracture, short stature, or dwarfism;
 - adult motor neuron disease, infantile spinal muscular atrophy, amyotrophic lateral sclerosis, juvenile spinal muscular atrophy, autoimmune motor neuropathy with multifocal conductor block, paralysis due to stroke or spinal cord injury, skeletal immobilization due to trauma, prolonged bed rest, voluntary inactivity, involuntary inactivity, metabolic stress or nutritional insufficiency, cancer, AIDS, fasting, a thyroid gland disorder, diabetes, benign congenital hypotonia, central core disease, burn injury, chronic obstructive pulmonary disease, liver diseases (examples such as fibrosis, cirrhosis), sepsis, renal failure, congestive heart failure, ageing, space travel or time spent in a zero gravity environment.

- 5 - age-related conditions such as sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, immunologic incompetence, high blood pressure, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, frailty, memory loss, wrinkles, impaired kidney function, and age-related hearing loss; metabolic disorders, including Type II Diabetes, Metabolic Syndrome, hyperglycemia, and obesity. Of course, patients may simultaneously suffer from one or more of these conditions, for example, sarcopenia and pulmonary emphysema, or sarcopenia and impaired kidney function.
- 10 - pathological disorders such as acute and/or chronic renal disease or failure, liver fibrosis or cirrhosis, cancer such as breast cancer, Parkinson's Disease; conditions associated with neuronal death, such as ALS, brain atrophy, or dementia and anemia. In addition, there are losses suffered as a consequence of age, trauma or inactivity.
- 15 - cachexia, particularly cachexia associated with a rheumatoid arthritis and cachexia associated with cancer.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12







Figure 1